This week, the PAX-D trial randomised its 100th participant to either the Pramipexole or placebo condition.
Randomisation occurs when a participant has successfully passed their screening visit and completed a short run-in period of phone calls and questionnaires with a trial research assistant.
This is a significant milestone for the trial, and we would like to express our sincere thanks to everyone who has contributed to this great achievement!
